Oral agents used for the management of type 2 diabetes mellitus include sulfonylureas, biguanides, thiazolidinediones, metglitinides, and/or α-glucosidase inhibitors. These medication classes can be further classified as hypoglycemic and antihyperglycemic agents. Hypoglycemia is a major symptom of toxicity of these agents, particularly with the sulfonylureas, including combination medications that include sulfonylureas. In overdose situations, metformin, a biguanide, can lead to considerable gastrointestinal adverse effects and potentially lactic acidosis in severe cases. Data on the management of toxicities of the other classes are limited. This article will review the treatment modalities that have been used for treating symptomatic hypoglycemia and metformin-induced lactic acidosis.
Williamson DF, Vinicor F, Bowman BA. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implication for health policy. Ann Intern Med. 2004;140:951-957.
2.
Engelgau MM, Geiss LS, Saaddine JB, et al.The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945-950.
3.
Carlton FB Jr.Recent advances in the pharmacologic management of diabetes mellitus. Emerg Med Clin North Am. 2000;18:745-753.
4.
Vaczek D.Top 200 prescription drugs of 2003. July 2004. Available at: www.pharmacytimes.com. Accessed November 5, 2004.
5.
Spiller HA. Management of antidiabetic medications in overdose. Drug Saf. 1998;19:411-424.
6.
Carr R, Zed PJ. Octreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother. 2002;36:1727-1732.
7.
Bosse GM. Antidiabetic and hypoglycemia agents. In: Goldfrank LR, ed. Goldfrank’s Toxicologic Emergencies. 7 th ed.New York, NY: McGraw-Hill; 2002:593-605.
Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681-1686.
10.
Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Harman JG, ed. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed.New York, NY: McGraw-Hill; 2001:1679-1714.
11.
Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am. 1989;18:163-183.
12.
Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993;76:752-756.
13.
Salas M, Caro JJ. Are hypoglycaemia and other adverse effects similar among sulphonylureas?Adverse Drug React Toxicol Rev. 2002;21:205-217.
14.
Watson WA, Litovitz TL, Rodgers GC Jr, et al.2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Ann Emerg Med. 2003;21:353-421.
Harrigan RA, Nathan MS, Beattie P.Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med. 2001;38:68-78.
Delaney KA. Antidotes in depth: dextrose. In: Goldfrank LR, ed. Goldfranks’s Toxicologic Emergencies. 7thed. New York, NY: McGraw-Hill; 2002:606-610.
19.
Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am. 1999;28:555-573.
20.
Howland MA. Antidotes in depth: octreotide. In: Goldfrank LR, ed. Goldfrank’s Toxicologic Emergencies. 7 th ed.New York, NY: McGraw-Hill; 2002:611-613.
21.
Chu J, Wang RY, Hill NS. Update in clinical toxicology. Am J Respir Crit Care Med. 2002;166:9-15.
22.
McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2000;36:133-138.
23.
Oates JA, Brown NJ. Antihypertensive agents and the drug therapy of hypertension. In Harman JG, ed. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed.New York, NY: McGraw-Hill; 2001:871-900.
24.
Palatnick W, Meatherall RC, Tenenbein M.Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med. 1991;151:1859-1862.
25.
Moore DF, Wood DF, Volans GN. Features, prevention and management of acute overdose due to antidiabetic drugs. Drug Saf. 1993;9:218-222.
26.
Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. Clin Toxicol. 2004;42:1-26.
27.
Neuvonen PJ, Karkkainen S.Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. Clin Pharmacol Ther. 1983;33:386-393.
28.
Bates N.Sulphonylurea and metformin overdose: clinical features and management. Emerg Nurse. 2001;9:18-22.
29.
Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63:1879-1894.
32.
Chitturi S, George J.Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, anti-diabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22:169-183.
33.
Salpeter S, Greyber E, Pasternak G, Salpeter E.Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2003(2):CD002967.
34.
Spiller HA, Quadrani DA. Toxic effects from metformin exposure. Ann Pharmacother. 2004;38:776-780.
35.
Khan JK, Pallaki M, Tolbert SR, Hornick TR. Lactic acidemia associated with metformin. Ann Pharmacother. 2003;37:66-69.
Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003;76:513-518.
38.
Spiller HA, Weber JA, Winter ML, et al.Multicenter case series of pediatric metformin ingestion. Ann Pharmacother. 2000;34:1385-1388.
39.
Teale KF, Devine A, Stewart H, Harper NJ. The management of metformin overdose. Anaesthesia. 1998;53:698-701.
40.
Barrueto F, Meggs WJ, Barchman MJ. Clearance of metformin by hemofiltration in overdose. J Toxicol Clin Toxicol. 2002;40:177-180.
41.
Doorenbos CJ, Bosma RJ, Lamberts PJ. Use of urea containing dialysate to avoid disequilibrium syndrome, enabling intensive dialysis treatment of a diabetic patient with renal failure and severe metformin induced lactic acidosis. Nephrol Dial Transplant. 2001;16:1303-1304.
42.
Heaney D, Majid A, Junor B.Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant. 1997;12:1046-1047.
43.
Gjedde S, Christiansen A, Pedersen SB, Rungby J.Survival following a metformin overdose of 63 g: a case report. Pharmacol Toxicol. 2003;93:98-99.
44.
Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care. 1999;22:1568-1577.
45.
Tugwood JD, Montague CT. Biology and toxicology of PPARgamma ligands. Hum Exp Toxicol. 2002;21:429-437.
46.
Chan KA, Truman A, Gurwitz JH, et al.A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003;163:728-734.
47.
Nesto RW, Bell D, Bonow RO, et al.Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-263.
48.
Hu S, Boettcher BR, Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia. 2003;46(suppl 1):M37-M43.
49.
Levien TL, Baker DE, Campbell RK, White JR Jr.Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother. 2001; 35:1426-1434.
50.
Flood TM. Serious hypoglycemia associated with misuse of repaglinide. Endocr Pract. 1999;5:137-138.
51.
Prandin (repaglinide) [product information]. Princeton, NJ: Novo Nordisk; October 2002.
52.
Starlix (nateglinide) [product information]. East Hanover, NJ: Novartis Pharmaceuticals; 2000.
53.
Devineni D, Walter YH, Smith HT, Lee JS, Prasad P, McLeod JF. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol. 2003;43:163-170.
54.
Hasslacher C.Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886-891.
55.
Nagai T, Imamura M, Iizuka K, Mori M.Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract. 2003;59:191-194.
56.
Yee HS, Fong NT. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy. 1996;16:792-805.
57.
Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;83:1515-1522.
58.
Sels JP, Huijberts MS, Wolffenbuttel BH. Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother. 1999;1:149-156.
59.
Mertes G.Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract. 2001;52:193-204.
